Misleading Millions: The American Cancer Society’s Flawed Mammogram
This article is copyrighted by GreenMedInfo LLC, 2024Visit our Re-post guidelines The American Cancer Society's rosy breast cancer statistics mask a deadly reality: mammograms may be doing more harm than good. Quick Summary: ACS report downplays severe risks of overdiagnosis and overtreatment from mammograms Pharmaceutical conf...
William Makis MD on X: "NEW ARTICLE: IVERMECTIN should be given to ALL Advanced Breast Cancer patients - outperforms chemo Paclitaxel and kills Cancer Stem Cells! A 2017 bombshell study by Mexican researchers should have changed how Breast Cancer is treated. Forever. In the 2017 paper "Ivermectin as https://t.co/n6J43gZgOl" / X
A 2017 bombshell study by Mexican researchers should have changed how Breast Cancer is treated. Forever.
In the 2017 paper "Ivermectin as…
— William Makis MD (@MakisMD)
The role of melatonin on miRNAs modulation in triple-negative breast cancer cells
Melatonin, a hormone secreted by pineal gland, exerts antimetastatic effects by reducing tumor cell proliferation, migration and invasion. MicroRNAs (miRNAs) are small, non-coding RNAs that play a crucial role in regulation of gene expression and biological processes of the cells. Herein, we search for a link between the tumor/metastatic-suppressive actions of melatonin and miRNA expression in triple-negative breast cancer cells. We demonstrated that melatonin exerts its anti-tumor actions by reducing proliferation, migration and c-Myc expression of triple negative breast cancer cells. By using Taqman-based assays, we analyzed the expression levels of a set of miRNAs following melatonin treatment of triple negative breast cancer cells and we identified 17 differentially expressed miRNAs, 6 down-regulated and 11 up-regulated. We focused on the anti-metastatic miR-148b and the oncogenic miR-210 both up-regulated by melatonin treatment and studied the effect of their modulation on melatonin-mediated impairment of tumor progression. Surprisingly, when miR-148b or miR-210 were depleted in triple-negative breast cancer cells, using a specific miR-148b sponge or anti-miR-210, melatonin effects on migration inhibition and c-myc downregulation were still visible suggesting that the increase of miR-148b and miR-210 expression observed following melatonin treatment was not required for the efficacy of melatonin action. Nevertheless, ours results suggest that melatonin exhibit a compound for metastatic trait inhibition, especially in MDA-MB-231 breast cancer cells even if a direct link between modulation of expression of certain proteins or miRNAs and melatonin effects has still to be established.
Polymorphisms in genes of melatonin biosynthesis and signaling support the light-at-night hypothesis for breast cancer | European Journal of Epidemiology
European Journal of Epidemiology - Light-at-night triggers the decline of pineal gland melatonin biosynthesis and secretion and is an IARC-classified probable breast-cancer risk factor. We applied...